Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
NBPE Announces January Monthly NAV Estimate
-
Total voting rights
-
Preliminary Statement of Results for the year ended 31 December 2024
-
Voting Rights and Capital
-
Total Voting Rights and Capital
-
Dividend payment ex-date of Arco Vara AS
-
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update
-
Exosens delivers very strong full-year 2024 results, overperforming on its IPO guidance; Sustained growth dynamic anticipated for 2025-2026
-
Exosens makes first US investment in night vision production capacity to address growing demand and benefit from new opportunities
-
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update
-
Transaction in Own Shares
-
BW Offshore: Ex dividend USD 0.14 today
-
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
-
Start of Day Message
-
ING acquires stake in Van Lanschot Kempen
-
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
-
SIKA ACQUIRES ONE OF THE LEADING ROOFING SYSTEM PROVIDERS IN THE UK
-
Subsidiaries of Aktsiaselts Infortar change business names
-
A2MAC1 Strengthens Global Sales Leadership to Enhance Client Proximity and Growth
-
Swift Navigation Works with STMicroelectronics to Launch End-to-End GNSS Solution for Automotive Autonomy
-
AGM Group Holdings Inc. Announces Pricing of $5.4 Million Public Offering
-
DNEG Wins Visual Effects Oscar® at 2025 Academy Awards
-
Apollo Names Shimpei Kanzaki as Japan Global Wealth Head
-
Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies
-
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
-
Wojciech Podobas Increases Stake in Thinca Co., Ltd. (TSE: 149A) to 6.00% Following Tokyo Visit
-
Update: SPS Chemical Fire Class Action Lawsuit Leadership Proposed; The Four Firms Jointly Filed Motions for Consolidation of All Pending, Future Cases Against the Defendant
-
BleeqUp Debuts Ranger, The World’s First 4-in-1 AI Cycling Camera Glasses at MWC 2025
-
Tickblaze Debuts a New Era of B2B Trading Solutions for Prop Firms, Hedge Funds, and Brokers
-
Initial Drill Results Prove Significant Polymetallic Mineralization at Mirasol’s Flagship Sobek Gold-Copper Project in the Vicuña District, Chile
-
Latin Metals Identifies Geophysical Anomalies at Cerro Bayo, Santa Cruz, Argentina
-
Bayport Intermediate Holdco PLC Quarterly Report December 2024
-
AMERICAN SALARS TO EXPAND ITS POCITOS PROJECT BY 1,635% TO 13,880 HECTARES IN ARGENTINA’S LITHIUM TRIANGLE
-
Nokia and industry partners accelerate AI-RAN development #MWC25
-
Ellomay Capital Announces Execution of Project Finance Agreements for its 198 MW Solar Portfolio in Italy
-
Acki Nacki Secures Over $6M in Preparation For Network Launch
-
CREEPZ Emerges from Stealth, Announces Flagship Games, Retail Drops & Major Partnerships
-
CREEPZ Emerges from Stealth, Announces Flagship Games, Retail Drops & Major Partnerships
-
Firefly Aerospace Becomes First Commercial Company to Successfully Land on the Moon
-
Bybit Web3 Pioneers AI Agent Acceleration: Launches First AI-DOL Reality Competition with $1M Prize
-
Free LwM2M Client by IoT Industry Leader
-
CGTN: How did China lay a good foundation for 2025 economic development
-
Austrian Fintech Company Talentir Just Solved YouTube's Billion-Dollar Payment Problem
-
Austrian Fintech Company Talentir Just Solved YouTube's Billion-Dollar Payment Problem
-
Notification of transaction by an Officer of Millicom (Tigo)
-
Notification of transaction by an Officer of Millicom (Tigo)
-
InfinixChain Introduces EVM-Compatible Layer 2 Blockchain Focused on Scalability and Low Fees
-
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
-
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
-
BexBack Introduces Double Deposit Bonus, $50 Welcome Bonus and 100x Leverage for Crypto Traders—No KYC Needed
